{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:30:55Z","timestamp":1777984255713,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04717-5","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T06:05:36Z","timestamp":1773727536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Corticosteroid use, bone density screening, and the influence of insurance in patients with inflammatory bowel disease: a retrospective analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6426-6552","authenticated-orcid":false,"given":"Anvit","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Landen Shane","family":"Burstiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niyati","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadim","family":"Qadir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Diaz-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianny","family":"Sulbaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Stemboroski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"4717_CR1","doi-asserted-by":"publisher","first-page":"691480","DOI":"10.3389\/fimmu.2021.691480","volume":"12","author":"S Bruscoli","year":"2021","unstructured":"Bruscoli S, et al. Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice. Front Immunol. 2021;12:691480. Print.","journal-title":"Front Immunol"},{"issue":"1","key":"4717_CR2","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/ajg.2011.58","volume":"106","author":"NJ Talley","year":"2011","unstructured":"Talley NJ, et al. An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease. Am J Gastroenterol. 2011;106(1):S2\u201325. quiz S26. Print.","journal-title":"Am J Gastroenterol"},{"key":"4717_CR3","doi-asserted-by":"publisher","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","volume":"8","author":"Z Cai","year":"2021","unstructured":"Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne). 2021;8:765474. Print.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"4717_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","volume":"10","author":"R Brattsand","year":"1996","unstructured":"Brattsand R, Linden M. Cytokine Modulation by Glucocorticoids: Mechanisms and Actions in Cellular Studies. Aliment Pharmacol Ther. 1996;10(2):81\u201390. discussion 91\u2009\u2013\u20092. Print.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"4717_CR5","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein JD, et al. Aga Clinical Practice Guidelines on the Medical Management Of moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s disease. Gastroenterology. 2021;160(7):2496\u2013508. Print.","journal-title":"Gastroenterology"},{"issue":"4","key":"4717_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/00002281-200307000-00013","volume":"15","author":"E Canalis","year":"2003","unstructured":"Canalis E. Mechanisms of Glucocorticoid-Induced Osteoporosis. Curr Opin Rheumatol. 2003;15(4):454\u20137. Print.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"4717_CR7","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1530\/EJE-15-0118","volume":"173","author":"F Mirza","year":"2015","unstructured":"Mirza F, Canalis E. Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015;173(3):R131\u201351. https:\/\/doi.org\/10.1530\/EJE-15-0118. PMID: 25971649; PMCID: PMC4534332.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"4717_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","volume":"3","author":"EJ Schoon","year":"2005","unstructured":"Schoon EJ, et al. Bone Mineral Density in Relation to Efficacy and Side Effects of Budesonide and Prednisolone in Crohn\u2019s Disease. Clin Gastroenterol Hepatol. 2005;3(2):113\u201321. Print.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"4717_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/j.1572-0241.2002.05609.x","volume":"97","author":"M Cino","year":"2002","unstructured":"Cino M, Greenberg GR. Bone Mineral Density in Crohn\u2019s Disease: A Longitudinal Study of Budesonide, Prednisone, and Nonsteroid Therapy. Am J Gastroenterol. 2002;97(4):915\u201321. Print.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"4717_CR10","doi-asserted-by":"publisher","first-page":"e0158017","DOI":"10.1371\/journal.pone.0158017","volume":"11","author":"AK Waljee","year":"2016","unstructured":"Waljee AK, et al. Corticosteroid Use and Complications in a Us Inflammatory Bowel Disease Cohort. PLoS ONE. 2016;11(6):e0158017. Print.","journal-title":"PLoS ONE"},{"key":"4717_CR11","doi-asserted-by":"publisher","unstructured":"A focused retrospective study on differences in IBD characteristics between black and white patients in the South, Burstiner, Landen Shane. Am J Med Sci. 365(6):488\u201395. https:\/\/doi.org\/10.1016\/j.amjms.2023.02.013.","DOI":"10.1016\/j.amjms.2023.02.013"},{"key":"4717_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/jcm13092652","volume":"13","author":"S Nancey","year":"2024","unstructured":"Nancey S, et al. Prevalence of the Oral Corticosteroid Exposure and Excessive Use in Patients with Inflammatory Bowel Disease: Data from Four French Referral Centers of the International Dice Study. J Clin Med. 2024;13:9. Print.","journal-title":"J Clin Med"},{"issue":"9","key":"4717_CR13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/apt.15497","volume":"50","author":"CP Selinger","year":"2019","unstructured":"Selinger CP, et al. Assessment of Steroid Use as a Key Performance Indicator in Inflammatory Bowel Disease-Analysis of Data from 2385 Uk Patients. Aliment Pharmacol Ther. 2019;50(9):1009\u201318. Print.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"4717_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/MIB.0000000000000008","volume":"20","author":"LE Targownik","year":"2014","unstructured":"Targownik LE, et al. Prevalence of and Outcomes Associated with Corticosteroid Prescription in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2014;20(4):622\u201330. Print.","journal-title":"Inflamm Bowel Dis"},{"key":"4717_CR15","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1007\/s00198-018-4586-6","volume":"29","author":"P Szafors","year":"2018","unstructured":"Szafors P, Che H, Barnetche T, Morel J, Gaujoux-Viala C, Combe B, Lukas C. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int. 2018;29:2389\u201397.","journal-title":"Osteoporos Int"},{"key":"4717_CR16","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.57187\/s.3407","volume":"154","author":"AS Kreienbuehl","year":"2024","unstructured":"Kreienbuehl AS, Rogler G, Emanuel B, Biedermann L, Meier C, Juillerat P, Restellini S, Hruz P, Vavricka SR, Aeberli D, Seibold F. Bone health in patients with inflammatory bowel disease. Swiss Med Wkly. 2024;154:3407.","journal-title":"Swiss Med Wkly"},{"issue":"24","key":"4717_CR17","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2018.7498","volume":"319","author":"SJ Curry","year":"2018","unstructured":"Curry SJ, et al. Screening for Osteoporosis to Prevent Fractures: Us Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(24):2521\u201331. Print.","journal-title":"JAMA"},{"key":"4717_CR18","unstructured":"Inflammatory Bowel Disease. (Ibd): Preventive care: corticosteroid related Iatrogenic. https:\/\/qpp.cms.gov\/docs\/QPP_quality_measure_specifications\/CQM-Measures\/2019_Measure_271_MIPSCQM.pdf."},{"key":"4717_CR19","unstructured":"Injury. \u2013 Bone Loss Assessment. Ed. Care, National Quality Strategy Domain: Effective Clinical2019. Print."},{"issue":"2","key":"4717_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ajg.2016.537","volume":"112","author":"FA Farraye","year":"2017","unstructured":"Farraye FA, et al. Acg Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017;112(2):241\u201358. Print.","journal-title":"Am J Gastroenterol"},{"key":"4717_CR21","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/ibd\/izz060","volume":"25","author":"JE Axelrad","year":"2019","unstructured":"Axelrad JE, et al. Increased Healthcare Utilization by Patients with Inflammatory Bowel Disease Covered by Medicaid at a Tertiary Care Center. Inflamm Bowel Dis. 2019;25:1711\u201317. Print.","journal-title":"Inflamm Bowel Dis"},{"key":"4717_CR22","doi-asserted-by":"publisher","unstructured":"AGA clinical practice update on noncolorectal cancer screening and vaccinations in patients with inflammatory bowel disease. Expert Review Caldera, Freddy Clin Gastroenterol Hepatol. 23(5):695\u2013706. https:\/\/doi.org\/10.1016\/j.cgh.2024.12.011.","DOI":"10.1016\/j.cgh.2024.12.011"},{"key":"4717_CR23","doi-asserted-by":"publisher","unstructured":"Kornbluth A, Sachar DB, and Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105(3)501\u2009\u201323. https:\/\/doi.org\/10.1038\/ajg.2009.727. quiz 24. Print.","DOI":"10.1038\/ajg.2009.727"},{"key":"4717_CR24","unstructured":"Equivalent Dosage of Commonly Used SCS, Published July. 2015. https:\/\/www.jacionline.org\/cms\/10.1016\/j.jaci.2015.07.046\/attachment\/9e6d93c6-b64b-4468-8cf5-38a0e9b551e9\/mmc2.pdf.\u00a0Accessed 8 Apr 2025."},{"issue":"5","key":"4717_CR25","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/ibd.20825","volume":"15","author":"GC Nguyen","year":"2009","unstructured":"Nguyen GC, et al. Hospitalizations for Inflammatory Bowel Disease: Profile of the Uninsured in the United States. Inflamm Bowel Dis. 2009;15(5):726\u201333. Print.","journal-title":"Inflamm Bowel Dis"},{"key":"4717_CR26","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/ecco-jcc\/jjaa019","volume":"147","author":"B Lo","year":"2020","unstructured":"Lo B, et al. Incidence, Risk Factors and Evaluation of Osteoporosis in Patients with Inflammatory Bowel Disease: A Danish Population-Based Inception Cohort with 10 Years of Follow-Up. J Crohns Colitis. 2020;147:904\u201314. Print.","journal-title":"J Crohns Colitis"},{"key":"4717_CR27","doi-asserted-by":"publisher","unstructured":"Wehbeh AMD, Phatharacharukul PMD, Fayad NF, MD. FACG1. 844\u2003Improvement of osteoporosis screening among IBD patients at GI Fellows\u2019 Clinics. Am J Gastroenterol. 2019;114:S489. https:\/\/doi.org\/10.14309\/01.ajg.0000592912.33515.ab.","DOI":"10.14309\/01.ajg.0000592912.33515.ab"},{"issue":"4","key":"4717_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/pds.4404","volume":"27","author":"HY Chang","year":"2018","unstructured":"Chang HY, et al. Impact of Florida\u2019s Prescription Drug Monitoring Program and Pill Mill Law on High-Risk Patients: A Comparative Interrupted Time Series Analysis. Pharmacoepidemiol Drug Saf. 2018;27(4):422\u201329. Print.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04717-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04717-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04717-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:11:08Z","timestamp":1776993068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04717-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4717"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04717-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6524164\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional board review was obtained for this retrospective review (IRB202202649) from the institutional board review at the University of Florida. Peter Iafrate, the IRB Chairman from the University of Florida approved the methods used to collect data included in this study. This study was approved as secondary research for which consent is not required: Secondary research use of identifiable private information or identifiable biospecimens, if at least one of the following criteria is met: the research involves only information collection and analysis involving the investigator's use of identifiable health information when that use is regulated under 45 CFR parts 160 and 164, subparts A and E, for the purposes of \u201chealth care operations\u201d or \u201cresearch\u201d as those terms are defined at 45 CFR 164.501 or for \u201cpublic health activities and purposes\u201d as described under 45 CFR 164.512(b).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors listed on this manuscript consent to publication. There are no identifying images, personal, or clinical details presented in this manuscript that compromise anonymity of those involved or studied.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"249"}}